tiprankstipranks
Deciphera Pharmaceuticals (DCPH)
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Ownership - Who Owns Deciphera Pharmaceuticals?

248 Followers

Recent Insider Trading Activity

Date
Name
Activity
Value
Apr 24, 2024Bought$481
Feb 20, 2024Sold$46986
Feb 20, 2024
Jama Pitman
Svp, Chief Development Officer
Sold$35388
Feb 20, 2024
Matthew Sherman
Evp & Chief Medical Officer
Sold$40820

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024Sold$154075
Mar 31, 2024Sold$80651957

Top Shareholders

Currently, No Data Available
Holder
# of Shares
Type
% Holding
Value

Top Mutual Fund Holders

Currently, No Data Available
Holder
# of Shares
Type
% Holding
Value

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,763,512Institution3.45%44,563,948
1,240,163Institution2.43%31,735,771
880,500Institution1.72%22,250,235
311,181Institution0.61%7,963,122
271,020Institution0.53%6,938,112
201,338Institution0.39%5,087,811
161,038Institution0.32%4,120,962
122,824Institution0.24%3,103,762
113,072Institution0.22%2,893,512
92,666Institution0.18%2,372,250

FAQ

Who Owns Deciphera Pharmaceuticals (DCPH)?
Currently, no data Available
What percentage of Deciphera Pharmaceuticals (DCPH) stock is held by institutional investors?
Currently, no data Available
What percentage of Deciphera Pharmaceuticals (DCPH) stock is held by retail investors?
Currently, no data Available
Who owns the most shares of Deciphera Pharmaceuticals (DCPH)?
Currently, no data Available
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
    What's Included in PREMIUM?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis